Olneyn leesiot (Finnish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Olneyn leesiot" in Finnish language version.

refsWebsite

Global rank Finnish rank

14nih.gov

4^th place

12^th place

9worldcat.org

5^th place

9^th place

8doi.org

2^nd place

10^th place

1sciencedirect.com

149^th place

237^th place

1sciencemag.org

857^th place

545^th place

1wiley.com

222^nd place

202^nd place

doi.org

dx.doi.org

GE Hardingham, H Bading: The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, helmikuu 2003, 26. vsk, nro 2, s. 81–89. PubMed:12536131 doi:10.1016/S0166-2236(02)00040-1 ISSN 0166-2236 Artikkelin verkkoversio.
CJ Reissig et al: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, syyskuu 2012, 223. vsk, nro 1, s. 1–15. PubMed:22526529 doi:10.1007/s00213-012-2680-6 ISSN 0033-3158 Artikkelin verkkoversio.
S Matsunaga, T Kishi, N Iwata: Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.4.2015, 10. vsk, nro 4. PubMed:25860130 doi:10.1371/journal.pone.0123289 ISSN 1932-6203 Artikkelin verkkoversio.
L Xiao et al: Switching of N-Methyl-d-aspartate (NMDA) Receptor-favorite Intracellular Signal Pathways from ERK1/2 Protein to p38 Mitogen-activated Protein Kinase Leads to Developmental Changes in NMDA Neurotoxicity. The Journal of Biological Chemistry, 10.6.2011, 286. vsk, nro 23, s. 20175–20193. PubMed:21474451 doi:10.1074/jbc.M110.188854 ISSN 0021-9258 Artikkelin verkkoversio.
GE Hardingham: Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochemical Society transactions, joulukuu 2009, 37. vsk, nro Pt 6, s. 1147–1160. PubMed:19909238 doi:10.1042/BST0371147 ISSN 0300-5127 Artikkelin verkkoversio.
JW Olney, J Labruyere, MT Price: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 16.6.1989, 244. vsk, nro 4910, s. 1360–1362. PubMed:2660263 doi:10.1126/science.2660263 ISSN 0036-8075 Artikkelin verkkoversio.
C Wang et al: Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Frontiers in Neuroanatomy, 17.7.2013, nro 7. PubMed:23882190 doi:10.3389/fnana.2013.00023 ISSN 1662-5129 Artikkelin verkkoversio.
CJA Morgan et al: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction, tammikuu 2010, 105. vsk, nro 1, s. 121–133. PubMed:19919593 doi:10.1111/j.1360-0443.2009.02761.x ISSN 1360-0443 Artikkelin verkkoversio.

nih.gov

pubmed.ncbi.nlm.nih.gov

GE Hardingham, H Bading: The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, helmikuu 2003, 26. vsk, nro 2, s. 81–89. PubMed:12536131 doi:10.1016/S0166-2236(02)00040-1 ISSN 0166-2236 Artikkelin verkkoversio.
CJ Reissig et al: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, syyskuu 2012, 223. vsk, nro 1, s. 1–15. PubMed:22526529 doi:10.1007/s00213-012-2680-6 ISSN 0033-3158 Artikkelin verkkoversio.
S Matsunaga, T Kishi, N Iwata: Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.4.2015, 10. vsk, nro 4. PubMed:25860130 doi:10.1371/journal.pone.0123289 ISSN 1932-6203 Artikkelin verkkoversio.
L Xiao et al: Switching of N-Methyl-d-aspartate (NMDA) Receptor-favorite Intracellular Signal Pathways from ERK1/2 Protein to p38 Mitogen-activated Protein Kinase Leads to Developmental Changes in NMDA Neurotoxicity. The Journal of Biological Chemistry, 10.6.2011, 286. vsk, nro 23, s. 20175–20193. PubMed:21474451 doi:10.1074/jbc.M110.188854 ISSN 0021-9258 Artikkelin verkkoversio.
GE Hardingham: Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochemical Society transactions, joulukuu 2009, 37. vsk, nro Pt 6, s. 1147–1160. PubMed:19909238 doi:10.1042/BST0371147 ISSN 0300-5127 Artikkelin verkkoversio.
JW Olney, J Labruyere, MT Price: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 16.6.1989, 244. vsk, nro 4910, s. 1360–1362. PubMed:2660263 doi:10.1126/science.2660263 ISSN 0036-8075 Artikkelin verkkoversio.
J Kornhuber et al: The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue. Acta Neuropathologica, heinäkuu 1999, 98. vsk, nro 1, s. 85–90. PubMed:10412804 ISSN 0001-6322
C Wang et al: Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Frontiers in Neuroanatomy, 17.7.2013, nro 7. PubMed:23882190 doi:10.3389/fnana.2013.00023 ISSN 1662-5129 Artikkelin verkkoversio.
CJA Morgan et al: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction, tammikuu 2010, 105. vsk, nro 1, s. 121–133. PubMed:19919593 doi:10.1111/j.1360-0443.2009.02761.x ISSN 1360-0443 Artikkelin verkkoversio.

ncbi.nlm.nih.gov

CJ Reissig et al: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, syyskuu 2012, 223. vsk, nro 1, s. 1–15. PubMed:22526529 doi:10.1007/s00213-012-2680-6 ISSN 0033-3158 Artikkelin verkkoversio.
S Matsunaga, T Kishi, N Iwata: Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.4.2015, 10. vsk, nro 4. PubMed:25860130 doi:10.1371/journal.pone.0123289 ISSN 1932-6203 Artikkelin verkkoversio.
L Xiao et al: Switching of N-Methyl-d-aspartate (NMDA) Receptor-favorite Intracellular Signal Pathways from ERK1/2 Protein to p38 Mitogen-activated Protein Kinase Leads to Developmental Changes in NMDA Neurotoxicity. The Journal of Biological Chemistry, 10.6.2011, 286. vsk, nro 23, s. 20175–20193. PubMed:21474451 doi:10.1074/jbc.M110.188854 ISSN 0021-9258 Artikkelin verkkoversio.
GE Hardingham: Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochemical Society transactions, joulukuu 2009, 37. vsk, nro Pt 6, s. 1147–1160. PubMed:19909238 doi:10.1042/BST0371147 ISSN 0300-5127 Artikkelin verkkoversio.
C Wang et al: Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Frontiers in Neuroanatomy, 17.7.2013, nro 7. PubMed:23882190 doi:10.3389/fnana.2013.00023 ISSN 1662-5129 Artikkelin verkkoversio.

sciencedirect.com

GE Hardingham, H Bading: The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, helmikuu 2003, 26. vsk, nro 2, s. 81–89. PubMed:12536131 doi:10.1016/S0166-2236(02)00040-1 ISSN 0166-2236 Artikkelin verkkoversio.

sciencemag.org

science.sciencemag.org

JW Olney, J Labruyere, MT Price: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 16.6.1989, 244. vsk, nro 4910, s. 1360–1362. PubMed:2660263 doi:10.1126/science.2660263 ISSN 0036-8075 Artikkelin verkkoversio.

wiley.com

onlinelibrary.wiley.com

CJA Morgan et al: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction, tammikuu 2010, 105. vsk, nro 1, s. 121–133. PubMed:19919593 doi:10.1111/j.1360-0443.2009.02761.x ISSN 1360-0443 Artikkelin verkkoversio.

worldcat.org

GE Hardingham, H Bading: The Yin and Yang of NMDA receptor signalling. Trends in Neurosciences, helmikuu 2003, 26. vsk, nro 2, s. 81–89. PubMed:12536131 doi:10.1016/S0166-2236(02)00040-1 ISSN 0166-2236 Artikkelin verkkoversio.
CJ Reissig et al: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology, syyskuu 2012, 223. vsk, nro 1, s. 1–15. PubMed:22526529 doi:10.1007/s00213-012-2680-6 ISSN 0033-3158 Artikkelin verkkoversio.
S Matsunaga, T Kishi, N Iwata: Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 10.4.2015, 10. vsk, nro 4. PubMed:25860130 doi:10.1371/journal.pone.0123289 ISSN 1932-6203 Artikkelin verkkoversio.
L Xiao et al: Switching of N-Methyl-d-aspartate (NMDA) Receptor-favorite Intracellular Signal Pathways from ERK1/2 Protein to p38 Mitogen-activated Protein Kinase Leads to Developmental Changes in NMDA Neurotoxicity. The Journal of Biological Chemistry, 10.6.2011, 286. vsk, nro 23, s. 20175–20193. PubMed:21474451 doi:10.1074/jbc.M110.188854 ISSN 0021-9258 Artikkelin verkkoversio.
GE Hardingham: Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochemical Society transactions, joulukuu 2009, 37. vsk, nro Pt 6, s. 1147–1160. PubMed:19909238 doi:10.1042/BST0371147 ISSN 0300-5127 Artikkelin verkkoversio.
JW Olney, J Labruyere, MT Price: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 16.6.1989, 244. vsk, nro 4910, s. 1360–1362. PubMed:2660263 doi:10.1126/science.2660263 ISSN 0036-8075 Artikkelin verkkoversio.
J Kornhuber et al: The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue. Acta Neuropathologica, heinäkuu 1999, 98. vsk, nro 1, s. 85–90. PubMed:10412804 ISSN 0001-6322
C Wang et al: Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Frontiers in Neuroanatomy, 17.7.2013, nro 7. PubMed:23882190 doi:10.3389/fnana.2013.00023 ISSN 1662-5129 Artikkelin verkkoversio.
CJA Morgan et al: Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction, tammikuu 2010, 105. vsk, nro 1, s. 121–133. PubMed:19919593 doi:10.1111/j.1360-0443.2009.02761.x ISSN 1360-0443 Artikkelin verkkoversio.